ISIN:US90466Y1038

EQS-News: Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive

Retrieved on: 
Sunday, December 18, 2022

In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.

Key Points: 
  • In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.
  • Renazorb utilizes a proprietary nanoparticle technology being developed by Unicycive for the treatment of hyperphosphatemia in CKD patients on dialysis.
  • Renazorb also has an added convenience for patients since it is swallowed with water instead of having to be chewed.
  • “Gaining early patient access and reimbursement for newly launched branded drugs can be a challenge” stated Doug Jermasek, Executive Vice President at Unicycive.

EQS-News: Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

Retrieved on: 
Friday, November 11, 2022

08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

Key Points: 

08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

EQS-News: Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

Retrieved on: 
Wednesday, October 12, 2022

While kidney cells make up only 1% of our body weight, they consume over 10% of our daily energy supply.

Key Points: 
  • While kidney cells make up only 1% of our body weight, they consume over 10% of our daily energy supply.
  • When either acute or chronic disease strikes these vital organs, the health of the mitochondria can literally be the difference between life and death.
  • The company is now beginning its next milestone, filing to begin Phase 1 human trials of the drug.
  • Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases.

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.